<?xml version="1.0" encoding="UTF-8"?>
<p id="p0105">Measures should be taken to ensure to continue pharmacotherapy and LA. Hospital-based therapies can be disrupted during a pandemic. Access to new LLT with easier administration than LA such as lomitapide (oral therapy) or those that can be less frequently administered such as an ANGPTL3-inhibitor, evinacumab (require hospital based IV administration) or inclisiran (if approved) could be useful during the outbreak and lockdown times.</p>
